ALZAI and Linus Health Forge AI-Driven Collaboration for Early Alzheimer's Risk Detection
核心洞察
ALZAI Health Corp. (搜索) and Linus Health (搜索) signed a non-binding MOU to explore combining their complementary AI technologies for earlier identification of Alzheimer's disease (搜索) risk and cognitive impairment (搜索).
The collaboration aims to integrate ALZAI's bloodwork-based risk algorithm with Linus Health (搜索)'s RADAR algorithm, digital cognitive assessments, and clinical decision support tools.
Potential applications include optimizing clinical trial recruitment, supporting healthcare provider engagement, and advancing dementia care workflows across pharma, CROs, and health systems.
Toronto-based ALZAI Health Corp. (搜索) (TSXV: ALZI) and Boston-based Linus Health (搜索) announced on August 11, 2026, that they have entered into a Memorandum of Understanding (MOU) to explore AI-driven collaborations aimed at earlier identification and assessment of Alzheimer's disease (搜索) risk and cognitive impairment (搜索). The non-binding agreement sets the stage for integrating two distinct but complementary risk-stratification platforms, potentially reshaping how at-risk patients are identified and triaged within existing clinical workflows.
The collaboration will investigate ways to combine ALZAI's AI-driven Alzheimer's disease (搜索) risk identification algorithm with Linus Health (搜索)'s RADAR (Risk of Alzheimer's and Dementia AlgoRithm) risk stratification algorithm, its Core Cognitive Evaluation (CCE) featuring the Digital Clock and Recall (DCR), and its clinical decision support tools. Together, the companies aim to build integrated solutions that span risk identification, cognitive assessment, and care pathway navigation.
Complementary Data, Unified Approach
Each company's technology draws on data already available in routine health records, eliminating the need for new or invasive testing. ALZAI's algorithm uses routine bloodwork and demographic data present in the medical record to stratify disease risk. Linus Health (搜索)'s RADAR builds on the published and validated eRADAR model, leveraging electronic health record (EHR) and claims data — including diagnostic codes, medication histories, and healthcare-utilization signals — to identify individuals at elevated risk. Following risk stratification, Linus Health's CCE assesses current cognitive performance, with results and recommended next steps delivered to clinicians within the existing care workflow.
"Risk stratification works best when it can use the signals already available in a patient's record," said Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health (搜索). "ALZAI uses routine blood tests, complementing our Radar algorithm, which draws on electronic health records or claims data. Together, these approaches can identify patients at elevated risk of Alzheimer's and other dementias who may benefit from cognitive evaluation."
Targeting the Broader Alzheimer's Ecosystem
The collaboration will focus on engaging pharmaceutical companies, contract research organizations (CROs), healthcare providers, healthcare systems, and research institutions. Key objectives include improving patient identification, optimizing clinical trial recruitment, supporting clinical workflow integration, and advancing earlier identification of individuals at elevated risk for Alzheimer's disease (搜索).
"We believe meaningful innovation in Alzheimer's disease (搜索) requires collaboration across complementary technologies," said Hayim Raclaw, CEO of ALZAI Health. "Linus Health (搜索) has established itself as a leader in digital cognitive assessment and brain health solutions. We believe that combining their capabilities with ALZAI's AI-driven disease-risk identification algorithm could support the development of more integrated solutions."
Beyond immediate commercial applications, the MOU framework also encompasses evaluation of technical integration opportunities, joint commercialization initiatives, funded research programs, grant applications, and future strategic agreements designed to accelerate adoption of AI-driven solutions across the Alzheimer's disease (搜索) ecosystem.
Non-Binding Framework with Forward-Looking Ambitions
The MOU is explicitly non-binding, and any commercial arrangement or definitive agreement arising from the collaboration will require separate negotiation and execution of definitive agreements by both parties. The companies caution that there can be no assurance the MOU will result in any definitive agreement, successful technology integration, funded research program, regulatory authorization, or future revenue.
ALZAI Health Corp. (搜索), listed on the TSX Venture Exchange, develops non-invasive, AI-driven disease risk identification solutions using routine healthcare data. Its proprietary platform has been validated on large-scale healthcare datasets and is designed for integration into electronic medical record systems, cloud-based environments, and enterprise healthcare platforms. Linus Health (搜索), a Boston-based digital health company, develops science-driven digital assessments and AI-enabled analytics to help clinicians and researchers identify cognitive change earlier and support more proactive, personalized intervention.